If the sample sizes are too small to split then RAP should be collecting more data before even thinking about doing a double blind study. Cross validation is an excellent way to test a model when you have limited data, but it has major limitations. You would be insane spending money doing an approval trial before you know your model is accurate and robust by testing on an independent validation data set.
- Forums
- ASX - By Stock
- RAP
- Ann: Positive Results from Australian Adult Clinical Studies
Ann: Positive Results from Australian Adult Clinical Studies, page-62
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)